| Date | Title | | | 11/23/10 | Neurocrine Biosciences to Present at the 22nd Annual Piper Jaffray Health Care Conference| LIVE AUDIO WEBCAST TUESDAY, NOVEMBER 30, 2010
SAN DIEGO, Nov. 23, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 22nd Annual Piper Jaffray Health Care Conference in New York.
The live presentation takes place on Tuesday, November 30, 2010 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time. The presentation will be webcast and may be ac... |
|  | | 11/22/10 | Neurocrine Biosciences Announces Successful Completion of Daisy PETAL Study| UPDATE TO TIMING OF END OF PHASE II MEETING
SAN DIEGO, Nov. 22, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.
"The previously announced improvements across all endometriosis-associated pain domains, during ... |
| | | 10/28/10 | Neurocrine Biosciences Reports Third Quarter 2010 Results| SAN DIEGO, Oct 28, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended September 30, 2010.
For the third quarter of 2010, the Company reported net income of $3.3 million, or $0.06 per share, compared with a net loss of $8.2 million, or $0.21 per share, for the same period in 2009. For the nine months ended September 30, 2010, the Company reported a net loss of $10.5 million, or $0.20 per share, as compared to... |
| | | 10/26/10 | Neurocrine Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference| Live Audio Webcast Tuesday, November 2, 2010
SAN DIEGO, Oct 26, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Oppenheimer 21st Annual Healthcare Conference in New York.
The live presentation takes place on Tuesday, November 2, 2010 at 11:25 a.m. Eastern Time / 8:25 a.m. Pacific Time. The presentation will be webcast and may be accessed... |
| | | 10/18/10 | Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results| Conference Call and Webcast Friday, October 29, 2010
SAN DIEGO, Oct 18, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2010 financial results after the Nasdaq market closes on Thursday, October 28, 2010. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Friday morning, October 29, 2010 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific T... |
| | | 10/18/10 | Neurocrine Biosciences Announces That VMAT2 Program Will Move Into Phase II Clinical Trials| SECOND PHASE I TRIAL OF VMAT2 INHIBITOR COMPLETED
SAN DIEGO, Oct 18, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The positive results of this Phase I study of repeated dosing in healthy volunteers allows the VMAT2 program to initiate Phase II studies.
"Our VMAT2 inhibitor was well tolerated and again s... |
| | | 09/14/10 | Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder| Study did not demonstrate a treatment effect compared to placebo.
SAN DIEGO, Sept 14, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode. This double-blind, placebo controlled trial randomized 150 patients into two treatment arms, 350 mg of GSK5616... |
| | | 09/09/10 | Neurocrine Biosciences to Present at Two Upcoming Conferences on September 16 and September 22| SAN DIEGO, Sept 09, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Stifel Nicolaus 2010 Healthcare Conference in Boston and at the UBS Global Life Sciences Conference in New York City.
The live presentation for the Stifel Nicolaus conference takes place on Thursday, September 16, 2010 at 10:20 a.m. Eastern Time / 7:20 a.m. Pacific Time.
... |
| | | 07/28/10 | Neurocrine Biosciences Reports Second Quarter 2010 Results| Updates guidance following two major strategic collaborations
SAN DIEGO, July 28, 2010 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the Company reported a net loss of $5.2 million, or $0.09 per share, compared with a net loss of $15.3 million, or $0.39 per share, for the same period in 2009. For the six months ended June 30, 2010, the Company reported a net loss ... |
| | | 07/22/10 | Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results| Conference Call and Webcast Thursday, July 29, 2010
SAN DIEGO, July 22, 2010 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2010 financial results after the Nasdaq market closes on Wednesday, July 28, 2010. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, July 29, 2010 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Tim... |
| | | 06/17/10 | -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes| SAN DIEGO, June 17, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potentia... |
| | | 06/16/10 | Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix| Conference Call and Webcast Wednesday, June 16, 2010
SAN DIEGO, June 16, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will host a conference call to report on the global agreement with Abbott for the exclusive worldwide development and commercialization of elagolix and the next-generation GnRH antagonists.
The live conference call and webcast will be held on Wednesday, June 16, 2010 at 8:45 a.m. Eastern Time (5:45 a.m. Pacific ... |
| | | 06/16/10 | Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis| ABBOTT PARK, Ill. and SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evalua... |
| | | 06/02/10 | Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference| SAN DIEGO, June 2, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2010 Global Life Sciences Conference and also at the 9th Annual Needham Healthcare Conference, both in New York.
The live presentation for the Jefferies conference takes place on Wednesday, June 9, 2010 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. The live p... |
| | | 05/24/10 | Neurocrine Biosciences Announces Positive Results in Daisy PETAL Study| PHASE II STUDY MEETS ALL EFFICACY ENDPOINTS
SAN DIEGO, May 24, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced statistically significant and clinically meaningful top-line efficacy results from its Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.
"The Daisy PETAL study was successful, all primary and secondary ... |
| | | 04/28/10 | Neurocrine Biosciences Reports First Quarter 2010 Results| SAN DIEGO, April 28, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $8.6 million, or $0.19 per share compared with a net loss of $19.7 million, or $0.51 per share, for the same period in 2009.
Revenues for the first quarter of 2010 were $0.8 million compared with $0.7 million for the same period last year. Revenue for both ... |
| | | 04/26/10 | Neurocrine Biosciences to Present at the Deutsche Bank 35th Annual Health Care Conference|
Live Audio Webcast Monday, May 3, 2010
SAN DIEGO, April 26, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 35th Annual Health Care Conference in Boston.
The live presentation takes place Monday, May 3, 2010 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time. The presentation will be simultaneously webcast and may be acces... |
| | | 04/22/10 | Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results| CONFERENCE CALL AND WEBCAST THURSDAY, APRIL 29, 2010
SAN DIEGO, April 22, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2010 financial results after the Nasdaq market closes on Wednesday, April 28, 2010. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, April 29, 2010 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific... |
| | | 04/13/10 | Neurocrine Biosciences Announces the Initiation of Second VMAT2 Phase I Clinical Trial| SAN DIEGO, April 13, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has received approval from Health Canada to commence its second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854.
"We are looking forward to starting our Phase I multiple repeated dose study of VMAT2 this month," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences. "Our VMAT2 inhibitor was well tolerated... |
| | | 03/16/10 | Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering| SAN DIEGO, March 16, 2010 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the underwriter of its recently completed public offering of common stock has exercised in full its option to purchase an additional 1,365,000 shares of common stock to cover over-allotments. The sale of the additional shares closed on March 16, 2010. When taking into account the sale of the additional shares at a price to the public of $2.20 per share, the aggregate gross procee... |
| | | 03/10/10 | Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference|
Live audio webcast Tuesday, March 16, 2010
SAN DIEGO, March 10, 2010 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Roth 22nd Annual OC Growth Conference in Laguna Niguel.
The live presentation takes place Tuesday, March 16, 2010 at 12:30 p.m. Eastern Time (ET)/9:30 a.m. Pacific Time (PT). The presentation will be simultaneously webcast and ... |
| | | 03/08/10 | Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference|
Live audio webcast Wednesday, March 10, 2010
SAN DIEGO, March 8, 2010 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 30th Annual Cowen & Co. Health Care Conference in Boston.
The live presentation takes place Wednesday, March 10, 2010 at 9:30 a.m. Eastern Time (ET)/6:30 a.m. Pacific Time (PT). The presentation will be simultaneously webc... |
| | | 03/05/10 | Neurocrine Biosciences, Inc. Prices Common Stock Offering| SAN DIEGO, March 5, 2010 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a price to the public of $2.20 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $20 million. The offering is expected to close on or about March 10, 2010, subject to customary clos... |
| | | 03/04/10 | Neurocrine Announces Proposed Public Offering of Common Stock| SAN DIEGO, March 4, 2010 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is the sole book-running manager for this offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The securities described above ar... |
| | | 02/08/10 | Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors| SAN DIEGO, Feb 08, 2010 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has appointed William H. Rastetter Ph.D. to its Board of Directors effective immediately. He is the current Chairman and Chief Executive Officer of Receptos, Inc., and former Executive Chairman of Biogen Idec, Inc.
"We are very pleased to welcome Bill Rastetter to our Board of Directors," said Joseph A. Mollica, Ph.D., Chairman of the Board of Neurocrine Biosciences. "The com... |
| | | 02/03/10 | Neurocrine Biosciences Reports Fourth Quarter and Year-End 2009 Results| SAN DIEGO, Feb 03, 2010 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and year ended December 31, 2009. For the three months ended December 31, 2009, the Company reported a net loss of $7.9 million or $0.20 loss per share compared to a net loss of $28.9 million or $0.75 loss per share for the same period last year. For the year ended December 31, 2009, the Company had a net loss of $51.0 million or $1.30 loss p... |
| | | 01/27/10 | Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results| Conference Call and Webcast Scheduled for Wednesday, February 3, 2010SAN DIEGO, Jan 27, 2010 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2009 financial results after the Nasdaq market closes on Wednesday, February 3, 2010. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, February 3, 2010 at 5:00 ... |
| |
|
